Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)
← catalyst calendarNCT07579910 · readout ≤ 2,569 d
Sponsored by Spruce Biosciences (industry) · SPRB — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
14estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Dec 2026 | estimated | When the study began enrolling |
| Primary completion | Aug 2033 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- MPS IIIB
Intervention
- Drug: Tralesinidase alfa (TA)
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in Bayley Scales of Infant and Toddler Development, Third Edition, Cognition Domain (BSID-III-C) Raw Score
measured Baseline to Week 260 (approximately 5 years)
Permalink · SPRB's whole pipeline · Catalyst calendar · Every registered study · What changed